vs
Side-by-side financial comparison of KFORCE INC (KFRC) and Bio-Techne (TECH). Click either name above to swap in a different company.
KFORCE INC is the larger business by last-quarter revenue ($330.4M vs $295.9M, roughly 1.1× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 2.4%, a 10.4% gap on every dollar of revenue. On growth, KFORCE INC posted the faster year-over-year revenue change (0.1% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -3.7%).
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
KFRC vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $330.4M | $295.9M |
| Net Profit | $7.9M | $38.0M |
| Gross Margin | 27.3% | 64.6% |
| Operating Margin | 3.6% | 18.4% |
| Net Margin | 2.4% | 12.8% |
| Revenue YoY | 0.1% | -6.4% |
| Net Profit YoY | -2.7% | 68.3% |
| EPS (diluted) | $0.46 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $330.4M | — | ||
| Q4 25 | $332.0M | $295.9M | ||
| Q3 25 | $332.6M | — | ||
| Q2 25 | $334.3M | $317.0M | ||
| Q1 25 | $330.0M | $316.2M | ||
| Q4 24 | $343.8M | $297.0M | ||
| Q3 24 | $353.3M | $289.5M | ||
| Q2 24 | $356.3M | $306.1M |
| Q1 26 | $7.9M | — | ||
| Q4 25 | $5.2M | $38.0M | ||
| Q3 25 | $11.1M | — | ||
| Q2 25 | $10.4M | $-17.7M | ||
| Q1 25 | $8.1M | $22.6M | ||
| Q4 24 | $11.1M | $34.9M | ||
| Q3 24 | $14.2M | $33.6M | ||
| Q2 24 | $14.2M | $40.6M |
| Q1 26 | 27.3% | — | ||
| Q4 25 | 27.2% | 64.6% | ||
| Q3 25 | 27.7% | — | ||
| Q2 25 | 27.1% | 62.7% | ||
| Q1 25 | 26.7% | 67.9% | ||
| Q4 24 | 27.0% | 65.3% | ||
| Q3 24 | 27.9% | 63.2% | ||
| Q2 24 | 27.8% | 66.4% |
| Q1 26 | 3.6% | — | ||
| Q4 25 | 2.6% | 18.4% | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 4.5% | -7.5% | ||
| Q1 25 | 3.5% | 12.2% | ||
| Q4 24 | 4.5% | 16.0% | ||
| Q3 24 | 5.3% | 13.8% | ||
| Q2 24 | 5.5% | 15.0% |
| Q1 26 | 2.4% | — | ||
| Q4 25 | 1.6% | 12.8% | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 3.1% | -5.6% | ||
| Q1 25 | 2.5% | 7.1% | ||
| Q4 24 | 3.2% | 11.7% | ||
| Q3 24 | 4.0% | 11.6% | ||
| Q2 24 | 4.0% | 13.3% |
| Q1 26 | $0.46 | — | ||
| Q4 25 | $0.29 | $0.24 | ||
| Q3 25 | $0.63 | — | ||
| Q2 25 | $0.59 | $-0.11 | ||
| Q1 25 | $0.45 | $0.14 | ||
| Q4 24 | $0.60 | $0.22 | ||
| Q3 24 | $0.75 | $0.21 | ||
| Q2 24 | $0.75 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $117.4M | $2.0B |
| Total Assets | $384.8M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.3M | — | ||
| Q4 25 | $2.1M | $172.9M | ||
| Q3 25 | $1.3M | — | ||
| Q2 25 | $2.5M | $162.2M | ||
| Q1 25 | $444.0K | $140.7M | ||
| Q4 24 | $349.0K | $177.5M | ||
| Q3 24 | $127.0K | $187.5M | ||
| Q2 24 | $110.0K | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $117.4M | — | ||
| Q4 25 | $124.6M | $2.0B | ||
| Q3 25 | $132.1M | — | ||
| Q2 25 | $134.4M | $1.9B | ||
| Q1 25 | $138.0M | $2.0B | ||
| Q4 24 | $154.6M | $2.1B | ||
| Q3 24 | $167.4M | $2.1B | ||
| Q2 24 | $166.6M | $2.1B |
| Q1 26 | $384.8M | — | ||
| Q4 25 | $365.6M | $2.5B | ||
| Q3 25 | $374.2M | — | ||
| Q2 25 | $373.6M | $2.6B | ||
| Q1 25 | $368.2M | $2.6B | ||
| Q4 24 | $357.8M | $2.7B | ||
| Q3 24 | $369.9M | $2.7B | ||
| Q2 24 | $362.7M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | $-7.4M | — |
| FCF MarginFCF / Revenue | -2.2% | — |
| Capex IntensityCapex / Revenue | 1.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $19.7M | — | ||
| Q3 25 | $23.3M | — | ||
| Q2 25 | $18.4M | $98.2M | ||
| Q1 25 | $249.0K | $41.1M | ||
| Q4 24 | $21.8M | $84.3M | ||
| Q3 24 | $31.0M | $63.9M | ||
| Q2 24 | $20.9M | $75.5M |
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $16.7M | — | ||
| Q3 25 | $19.8M | — | ||
| Q2 25 | $14.2M | $93.3M | ||
| Q1 25 | $-3.9M | $31.0M | ||
| Q4 24 | $20.9M | $77.5M | ||
| Q3 24 | $27.5M | $54.7M | ||
| Q2 24 | $17.8M | $57.5M |
| Q1 26 | -2.2% | — | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 4.3% | 29.4% | ||
| Q1 25 | -1.2% | 9.8% | ||
| Q4 24 | 6.1% | 26.1% | ||
| Q3 24 | 7.8% | 18.9% | ||
| Q2 24 | 5.0% | 18.8% |
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 0.3% | 2.3% | ||
| Q3 24 | 1.0% | 3.2% | ||
| Q2 24 | 0.9% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | — | ||
| Q3 25 | 2.11× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | 0.03× | 1.82× | ||
| Q4 24 | 1.97× | 2.42× | ||
| Q3 24 | 2.18× | 1.90× | ||
| Q2 24 | 1.48× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KFRC
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
